Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BIRC3 (cIAP2) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BIRC3 Recombinant Protein (BIR1-3 / Full Length / Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for FP/TR-FRET binding assays. |
View BIRC3 Products |
| Gene Delivery | BIRC3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View BIRC3 Products |
| Benchmark Ab | Anti-BIRC3 Benchmark Antibody Recombinant positive control for western blot, IP, and IHC validation. |
View BIRC3 Products |
| Validator | BIRC3 siRNA Set For knockdown verification and functional assay specificity checks. |
View BIRC3 Products |
| Related Target A | BIRC2 (cIAP1) High homology partner. Critical for selectivity screening of SMAC mimetics and dual/pan-IAP degraders. |
View BIRC2 Products |
| Related Target B | BIRC4 (XIAP) Key anti-apoptotic protein. Evaluated alongside BIRC3 to ensure therapeutic index differentiation. |
View BIRC4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling (cIAP1 vs. cIAP2 vs. XIAP) | High-purity recombinant BIR domain panels strictly verified by mass spectrometry and sequence analysis. |
| Intracellular target validation | Lentiviral vectors for stable cell line generation to preserve native conformation and downstream signaling cascade. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live BIRC3 (cIAP2) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of BIRC3 (cIAP2) is undergoing a significant transition. Historically approached via SMAC mimetics (IAP antagonists), the focus is shifting toward targeted protein degradation (PROTACs/degraders) and combination immunotherapies. BIRC3 acts as a key negative regulator of the non-canonical NF-κB pathway and a suppressor of necroptosis. As first-generation pan-IAP inhibitors face therapeutic window limitations, next-generation drug discovery demands highly selective molecules or multi-specific degraders capable of discriminating between BIRC2 (cIAP1), BIRC3 (cIAP2), and BIRC4 (XIAP).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| SMAC Mimetics / Small Molecules | Debiopharm, Ascentage Pharma, Astex Pharmaceuticals | Solid Tumors, Hematological Malignancies | Selectivity Assay (Need High-Purity Recombinant BIRC2, BIRC3, and XIAP BIR domains) |
| PROTACs / Degraders | Arvinas, Kymera Therapeutics, Academic Labs | Oncology, Autoimmune Diseases | Ternary Complex Validation (Need Sequence-Verified BIRC3 Mutant and Wild-Type Proteins) |
| Combination Biologics | Merck, Bristol Myers Squibb | PD-1/PD-L1 Resistant Tumors | Cell-based Apoptosis / Necroptosis Assays (Need Lentivirus for Stable Cell Lines) |